FRANKLIN, Tenn., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement company committed to bringing access to great healthcare to everyone on Medicare, today released research demonstrating Clover Assistant’s impact on medication adherence. The paper, Clover Assistant Use and Medication Adherence for Common Chronic Conditions, examines the correlation between Primary Care Physician (PCP) use of Clover Assistant and levels of adherence to prescribed medications for common chronic conditions including diabetes, high blood pressure, and high cholesterol.
The lead author of the study, Dr. Kumar Dharmarajan, Chief Medical Officer of Clover Assistant, Adjunct Professor at Yale, and practicing cardiologist said, “Clinicians have no idea if patients pick up their prescribed medications at the pharmacy. This is a glaring blindspot. While it may seem simple, letting doctors know that their patients have not picked up their refills can prompt conversations to understand the root cause of the non-adherence and drive meaningful increases in medication fills, as our research shows. We know that taking medications regularly for chronic health conditions lowers complications and reduces healthcare costs.”
This is the third retrospective data analysis conducted by the company to measure the clinical impact of Clover Assistant on the identification and management of chronic diseases. The previous analyses focus on the diagnosis, treatment and progression of Diabetes and Chronic Kidney Disease.
To learn more about Clover Assistant visit: www.cloverassistant.com
Clover Health (Nasdaq: CLOV) is a physician enablement company committed to bringing access to great healthcare to everyone on Medicare. This includes a health equity-based focus on seniors who have historically lacked access to affordable, high-quality healthcare. Our strategy is powered by our software platform, Clover Assistant, which is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease.
Press Contact:
Andrew Still-Baxter
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations Contact:
Ryan Schmidt
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$2.69 |
Daily Change: | -0.11 -3.93 |
Daily Volume: | 5,415,598 |
Market Cap: | US$1.130B |
October 06, 2025 September 25, 2025 September 16, 2025 September 09, 2025 August 05, 2025 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load